Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: A 2-year analytical review

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Chiu, Chun Kai ^a   Kuo, Ming Chun ^b   Yu, Shan Fu ^b   Su, Ben Yu Jih ^b   Cheng, Tien Tsai ^b  

^a I SHOU UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adherence; Compliance; Osteoporosis regimens; Persistence

Indexed keywords

ADULT; AGED; ARTICLE; BONE DENSITY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; OSTEOPOROSIS; PRESCRIPTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SPINE FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DRUG PRESCRIPTIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OSTEOPOROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TAIWAN; TIME FACTORS;

EID: 84884395090     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-276     Document Type: Article

References (47)

1. Osteoporosis epidemiology update. Cole ZA, Dennison EM, Cooper C, Curr Rheumatol Rep 2008 10 2 92 96 10.1007/s11926-008-0017-6 18460262
2. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Johnell O, Kanis J, Gullberg G, Calcif Tissue Int 2001 69 4 182 184 10.1007/s00223-001-1045-7 11730245 (Pubitemid 33035382)
3. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Cree MW, Juby AG, Carriere KC, Osteoporos Int 2003 14 9 722 727 10.1007/s00198-003-1430-3 12904833 (Pubitemid 37295833)
4. Elderly patient's mortality and morbidity following trochanteric fracture. A prospective study of 100 cases. Mnif H, Koubaa M, Zrig M, Trabelsi R, Abid A, Orthop Traumatol Surg Res 2009 95 7 505 510 10.1016/j.otsr.2009.08. 001 19783240
5. Osteoporosis in Men. Watts NB, Endocr Pract 2013 11 1 16
6. Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. Romagnoli E, Del Fiacco R, Russo S, Piemonte S, Fidanza F, Colapietro F, Diacinti D, Cipriani C, Minisola S, J Rheumatol 2011 38 8 1671 1679 10.3899/jrheum.110030 21632675
7. Estimated prevalence of osteoporosis from a Nationwide Health Insurance database in Taiwan. Yang NP, Deng CY, Chou YJ, Chen PQ, Lin CH, Chou P, Chang HJ, Health Policy 2006 75 3 329 337 10.1016/j.healthpol.2005.04.009 15946761 (Pubitemid 43042365)
8. Quality of life, morbidity, and mortality after low trauma hip fracture in men. Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ, Ann Rheum Dis 2006 65 1 87 92 10.1136/ard.2004.034611 16079173 (Pubitemid 41815645)
9. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA, Lancet 1999 353 9156 878 882 10.1016/S0140-6736(98)09075-8 10093980 (Pubitemid 29126875)
10. Osteoporosis in men. Gennari L, Bilezikian JP, Endocrinol Metab Clin North Am 2007 36 2 399 419 10.1016/j.ecl.2007.03.008 17543726 (Pubitemid 46817889)
11. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Eichner SF, Lloyd KB, Timpe EM, Ann Pharmacother 2003 37 5 711 724 12708951 (Pubitemid 36523069)
12. Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence-based clinical perspective. Geusens PP, Roux CH, Reid DM, Lems WF, Adami S, Adachi JD, Sambrook PN, Saag KG, Lane NE, Hochberg MC, Nat Clin Pract Rheumatol 2008 4 5 240 248 18398411 (Pubitemid 351638681)
13. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ, Mayo Clin Proc 2007 82 12 1493 1501 18053457 (Pubitemid 350211697)
14. Adherence to alendronate in male veterans. Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME, Osteoporos Int 2008 19 3 349 356 10.1007/s00198-007-0471-4 17898921 (Pubitemid 351199186)
15. The relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients. Cevikoi A, Umay E, Polat S, Ecerkale O, Cakci A, Clinics (Sao Paulo) 2011 66 4 579 582 10.1590/S1807- 59322011000400010
16. Adherence to treatment of osteoporosis: a need for study. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, et al. Osteoporos Int 2007 18 10 1311 1317 10.1007/s00198-007-0410-4 17585359 (Pubitemid 47389473)
17. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Gold DT, Alexander IM, Ettinger MP, Ann Pharmacother 2006 40 6 1143 1150 10.1345/aph.1G534 16735667 (Pubitemid 43886973)
18. Comparison of drug adherence rates among patients with seven different medical conditions. Briesacher BA, Andrade SE, Fouayzi H, Chan KA, Pharmacotherapy 2008 28 4 437 443 10.1592/phco.28.4.437 18363527 (Pubitemid 351466455)
19. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, et al. J Bone Miner Res 2004 19 8 1259 1269 10.1359/JBMR.040326 15231012 (Pubitemid 41094366)
20. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, et al. JAMA 2006 296 24 2927 2938 10.1001/jama.296.24.2927 17190893 (Pubitemid 46021497)
21. Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in The Netherlands. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ, Osteoporos Int 2011 22 5 1537 1546 10.1007/s00198-010-1372-5 20838773
22. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Cotté FE, Fardellone P, Mercier F, Gaudin AF, Roux C, Osteoporos In 2010 21 1 145 155 10.1007/s00198-009-0930-1
23. Dawson-Hughes B, Lindsay R, Khosla S, Melton L, Tosteson A, Favus M, Clinician's Guide to Prevention and Treatment of Osteoporosis Washington DC: National Osteoporosis Foundation 2008 24069435
24. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis, Arthritis Rheum 2001 44 7 1496 1503 11465699
25. Medication compliance and persistence: terminology and definitions. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK, Value Health 2008 11 1 44 47 10.1111/j.1524-4733.2007.00213.x 18237359 (Pubitemid 351160875)
26. Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study. Yu SF, Chou CL, Lai HM, Chen YC, Chiu CK, Kuo MC, Su YJ, Chen CJ, Cheng TT, Int J Rheum Dis 2012 15 3 297 305 10.1111/j.1756-185X.2012.01719.x 22709492
27. Compliance with drug therapy for postmenopausal osteoporosis. Weycker D, Macarios D, Edelsberg J, Oster G, Osteoporos Int 2006 17 11 1645 1652 10.1007/s00198-006-0179-x 16862397 (Pubitemid 44477625)
28. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Recker RR, Gallagher R, MacCosbe PE, Mayo Clin Proc 2005 80 7 856 861 10.4065/80.7.856 16007889 (Pubitemid 40911458)
29. Compliance with osteoporosis medications. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA, Arch Intern Med 2005 165 20 2414 2419 10.1001/archinte.165.20.2414 16287772 (Pubitemid 41640855)
30. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Lin TC, Yang CY, Yang YH, Lin SJ, Clin Pharmacol Ther 2011 90 1 109 116 10.1038/clpt.2011.62 21525868
31. Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Landfeldt E, Strom O, Robbins S, Borgstrom F, Osteoporos Int 2012 23 2 433 443 10.1007/s00198-011- 1549-6 21286686
32. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH, South Med J 2006 99 6 570 575 10.1097/01.smj.0000221637.90495.66 16800411 (Pubitemid 43999919)
33. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. Clowes JA, Peel NF, Eastell R, J Clin Endocrinol Metab 2004 89 3 1117 1123 10.1210/jc.2003-030501 15001596 (Pubitemid 38368399)
34. Compliance with pharmacologic therapy for osteoporosis. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E, Osteoporos Int 2003 14 12 965 968 10.1007/s00198-003-1502-4 14504697 (Pubitemid 40824268)
35. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, Huang KE, Osteoporos Int 2013 24 2 511 521 10.1007/s00198-012-1984-z 22588182
36. Compliance with drug therapies for the treatment and prevention of osteoporosis. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J, Maturitas 2004 48 3 271 287 10.1016/j.maturitas.2004.02.005 15207894 (Pubitemid 38781153)
37. Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. Boonen S, Kay R, Cooper C, Haentjens P, Vanderschueren D, Callewaert F, Milisen K, Ferrari S, Int J Clin Pract 2009 63 12 1792 1804 10.1111/j.1742-1241.2009.02206.x 19845802
38. Persistence with weekly alendronate therapy among postmenopausal women. Lo JC, Pressman AR, Omar MA, Ettinger B, Osteoporos Int 2006 17 6 922 928 10.1007/s00198-006-0085-2 16609824 (Pubitemid 43781507)
39. Review of adherence to medications for the treatment of osteoporosis. Gold DT, Silverman S, Curr Osteoporos Rep 2006 4 1 21 27 10.1007/s11914-006- 0011-8 16527004 (Pubitemid 44623944)
40. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Carnevale V, Nieddu L, Romagnoli E, Bona E, Piemonte S, Scillitani A, Minisola S, Osteoporos Int 2006 17 3 478 483 10.1007/s00198-005-0010-0 16283066
41. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ, Pharmacoepidemiol Drug Saf 2012 21 3 297 304 10.1002/pds.2344 22237942
42. Determinants of adherence to osteoporosis treatment in clinical practice. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Osteoporos Int 2006 17 6 914 921 10.1007/s00198-006-0073-6 16538553 (Pubitemid 43781506)
43. Physician specialty is associated with adherence to treatment guidelines for acute otitis media in children. Grossman Z, Silverman BG, Miron D, Acta Paediatr 2013 102 1 29 33 10.1111/apa.12051 23057496
44. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y, Osteoporos Int 2007 18 10 1421 1427 10.1007/s00198-007-0406-0 17577595 (Pubitemid 47389472)
45. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, Spettell CM, Weissman NW, Wilke S, Saag KG, Arthritis Rheum 2005 52 8 2485 2494 10.1002/art.21194 16052570 (Pubitemid 41117436)
46. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Pickney CS, Arnason JA, Osteoporos Int 2005 16 9 1156 1160 10.1007/s00198-004-1818-8 15744452 (Pubitemid 41225103)
47. Adherence with bisphosphonate therapy in us veterans with rheumatoid arthritis. Richards JS, Cannon GW, Hayden CL, Amdur RL, Lazaro D, Mikuls TR, Reimold AM, Caplan L, Johnson DS, Schwab P, et al. Arthritis Care Res (Hoboken) 2012 64 12 1864 1870 10.1002/acr.21777